SGLT2 inhibitor use was associated with a significantly lower risk of the composite outcome of ventricular arrhythmias and cardiac arrests, with an HR of 0.76 (95% CI 0.71‐0.81; log‐rank P value 0.0059 [Table 3]). This evidence concerns the gene SLC5A2 and cardiac arrest.